CR Pharmaceutical
China Resources Pharmaceutical Group Limited (CR Pharmaceutical) is one of the top three integrated pharmaceutical companies specializing in R&D, manufacturing, distribution, and retail of medicines and nutraceutical products. Since going public, CR Pharmaceutical has been included in several important capital market indexes and ranked 63rd in the Fortune China 500 list in 2021.
CR Pharmaceutical has many subsidiaries, including CR Pharmaceutical Commercial Group, CR Sanjiu Medical & Pharmaceutical, CR Double-Crane Pharmaceutical, and more. In 2021, the company's revenue reached HK$236.806 billion, and the net profit reached HK$6.647 billion.
The company's pharmaceutical business ranks among the top three in the industry, with a business network covering the entire country. CR Pharmaceutical has established 330 subsidiaries and branches in 28 provinces and cities, operating a total of 208 modern logistics centers that provide highly specialized and efficient supply chain services for upstream and downstream customers. They also operate one of the largest retail pharmacy networks in China, including 211 DTP (direct-to-patient) specialized pharmacies.
CR Pharmaceutical is committed to "Protecting Human Health and Improving Quality of Life," and they plan to seize opportunities for developing and transforming China's healthcare industry. They aim to become a leader in the pharmaceutical and health industry, trusted by the public and driven by innovation. Overall, CR Pharmaceutical is a major player in the Chinese pharmaceutical industry, with a diverse range of products and services.
Founded: 1938
Headquarters: Wanchai, Hong Kong
Website: https://www.crpharm.com/EN/acp/au/
